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Abstract
Purpose To determine the impact on clinical management of patients with high-risk (HR) prostate cancer at diagnosis and
patients with biochemical recurrence (BCR) using a new kit form of 68Ga-prostate-specific membrane antigen (PSMA), namely
tris(hydroxypyridinone) (THP)-PSMA, with positron emission tomography-computed tomography (PET-CT).
Methods One hundred eighteen consecutive patients (50 HR, 68 BCR) had management plans documented at a multi-
disciplinary meeting before 68Ga-THP-PSMA PET-CT. Patients underwent PET-CT scans 60-min post-injection of 68Ga-
THP-PSMA (mean 159 ± 21.2 MBq). Post-scan management plans, Gleason score, prostate-specific antigen (PSA) and
PSA doubling time (PSAdt) were recorded.
Results HR group: 12/50 (24%) patients had management changed (9 inter-modality, 3 intra-modality). Patients with PSA < 20
μg/L had more frequent management changes (9/26, 34.6%) compared with PSA > 20 μg/L (3/24, 12.5%). Gleason scores > 8
were associated with detection of more nodal (4/16, 25% vs 5/31, 16.1%) and bone (2/16, 12.5% vs 2/31, 6.5%) metastases. BCR
group: Clinical management changed in 23/68 (34%) patients (17 inter-modality, 6 intra-modality). Forty out of 68 (59%) scans
were positive. Positivity rate increased with PSA level (PSA < 0.5 μg/L, 0%; PSA 0.5–1.0 μg/L, 35%; PSA 1.0–5.0 μg/L, 69%;
PSA 5.0–10.0 μg/L, 91%), PSAdt of < 6 months (56% vs 45.7%) and Gleason score > 8 (78.9% vs 51.2%).
Conclusions 68Ga-THP-PSMA PET-CT influences clinical management in significant numbers of patient with HR prostate
cancer pre-radical treatment and is associated with PSA. Management change also occurs in patients with BCR and is associated
with PSA and Gleason score, despite lower scan positivity rates at low PSA levels < 0.5 μg/L.
Keywords Prostate-specific membrane antigen . Prostate cancer . PSMA-PET-CT .Management impact . 68Ga-THP-PSMA
Introduction
Prostate cancer is the most commonly diagnosed malignancy in
men and is a leading cause of cancer-related death [1, 2].
Accurate staging of prostate cancer before radical treatment
and for the detection of recurrence is vital for directing treatment
and predicting prognosis [3]. This has conventionally been de-
pendent upon digital rectal examination, prostate-specific anti-
gen (PSA) testing and prostate biopsy, complemented with im-
aging, including multiparametric MRI (mpMRI), computed to-
mography (CT) and bone scintigraphy [4].
More recently, positron emission tomography-computed
tomography (PET-CT), with tracers such as 18F-choline,
has increasingly played a role in the management of these
patients [5, 6]. However, sensitivity is only moderate for
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detecting nodal metastases [5] or in those with low PSA
levels at biochemical recurrence (BCR) [7]. This has led to
the investigation of more prostate-specific tracers with
greater diagnostic accuracy.
Prostate-specific membrane antigen (PSMA) is a type
II transmembrane glycoprotein with significantly in-
creased expression in prostate cancer cells compared with
benign tissue [8]. It has emerged as a potential disease
biomarker for imaging and targeted treatment. Several en-
zymes with structural and functional homology to PSMA
have been identified leading to the possibility of
exploiting these small molecules for the imaging and
treatment of prostate cancer via PSMA-targeting [9].
The clinical breakthrough of PET imaging with
PSMA ligands was achieved with 68Ga-HBED-CC-
PSMA, also referred to as 68Ga-PSMA-11 [10, 11].
This compound has a strong binding affinity for
PSMA and highly efficient internalisation into the pros-
tate cancer cell. Since 2011, the use of PSMA PET
ligands, predominantly 68Ga-HBED-CC-PSMA, has
gained rapid acceptance with excellent diagnostic perfor-
mance in BCR, with an ability to detect lesions at low
PSA levels, but also in primary staging [9, 12, 13].
A n o v e l c o l d - k i t f o r m u l a t i o n , 6 8 G a - t r i s
(hydroxypyridinone)-PSMA (68Ga-THP-PSMA), has been
introduced that allows more rapid radiolabelling using a
single-step kit [14, 15]. It features the THP ligand, which
forms complexes with 68Ga rapidly at a low concentration
at room temperature and over a wide pH range.
Evaluations have demonstrated a favourable bio-
distribution and affinity for targeting PSMA [14–16].
Whilst 68Ga-HBED-CC-PSMA PET-CT has been shown
to impact management in between 39 and 62% of patients
with BCR of prostate cancer after previous definitive
treatment and in 21% of patients undergoing primary stag-
ing, no such data has yet been reported for 68Ga-THP-
PSMA [17, 18].
We hypothesised that 68Ga-THP-PSMA PET-CT im-
pacts clinical management in prostate cancer in high-
risk (HR) patients before planned curative treatment
and following BCR.
Our aim was to prospectively record changes in intended
treatment plans in both groups of patients in a tertiary prostate
cancer service.
Materials and methods
Patient data and management
A questionnaire was adapted from Roach et al. to record
management plans before and after 68Ga-THP-PSMA
PET-CT [17] (Appendix 1). Patients with high-risk (HR)
prostate cancer (defined by the D’Amico classification)
before surgery or radiation therapy, or patients with
BCR, defined by the American Society for Therapeutic
Radiology and Oncology (ASTRO) criteria, were eligible
[19, 20]. This service evaluation was granted institutional
approval by the Guy’s and St Thomas’ Service Evaluation
committee and the requirement for consent for data use
that was anonymised before analysis was waived.
A pre-PET-CT management plan was prospectively
documented on the questionnaire at a multidisciplinary
meeting (MDM) consisting of urologists, oncologists, his-
topathologists, radiologists and a nuclear medicine physi-
cian. PSA at diagnosis or at recurrence, PSA doubling
time (PSAdt) in those with BCR and Gleason score at
diagnosis or at recurrence were recorded. Results of con-
ventional prior imaging were used to inform management.
All patients undergoing primary staging have a
multiparametric MRI as part of their routine diagnostic
evaluation. Any subsequent validation information for
the 68Ga-THP-PSMA PET-CT results, including histology
and post-PSMA PET-CT conventional imaging up to 6
months, was evaluated.
The post-68Ga-THP-PSMA PET-CT management plan
resulting from MDM discussion or clinical review was
recorded on the questionnaire. Any cases where the man-
agement plan remained unclear were reviewed by a clin-
ical oncologist who assessed the post-68Ga-THP-PSMA
PET-CT scan treatment plan according to local and na-
tional treatment guidelines. The management change was
recorded as either intra-modality or inter-modality. Inter-
modality change was defined as an alteration in the type
of management (e.g. cancellation of salvage radiotherapy
(RT) due to poly-metastatic disease demonstrated on
68Ga-THP-PSMA PET-CT, whereas intra-modality change
was defined as a modification of dose/site/strategy that
was previously indicated.
Radiochemistry
68Ga-THP-PSMA was prepared using a kit preparation
(GalliProst™) containing 40.0 μg tris(hydroxypyridinone)-
Glu-urea-Lys(Ahx), sodium bicarbonate, mannitol and phos-
phate buffer.
Gallium-68 from a Ge-68/Ga-68 generator with a Ge-
68 breakthrough of ≤ 0.001 % was directly eluted into the
kit vial. The generator was eluted within 5 mL of 0.1 M
HCl(aq). The kit solution was incubated for 5 min at room
temperature for complete labelling with a vent needle in
situ to clear excess carbon dioxide produced during the
labelling process.
68Ga-THP-PSMA was analysed according to the mono-
graphs 2462 (gallium chloride) and 2482 (gallium
edotreotide) of the European Pharmacopeia. Radioanalytic
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thin layer chromatography (TLC) was performed using
glass microfiber chromatography paper impregnated with
a silica gel (Agilent technologies) and 10% ammonium
acetate in water/methanol (030:70) and also with citrate
cugger pH 5. The radio-iTLCs were analysed on a
MiniGita thin-layer chromatography scanner.
High-performance liquid chromatography (radio-HPLC)
was performed on a Varian ProStar high-pressure gradient
system equipped with an ultraviolet-visible detector (Varian
ProStar 335) and a radiodetector using a RP-18 column.
Radiochemical purity and yield were > 95%.
68Ga-THP-PSMA PET-CT scan
No specific patient preparation was required except blad-
der voiding immediately before imaging. All patients
were injected intravenously with 68Ga-THP-PSMA (mean
159 ± 21.2 MBq). At 60 min, a scan was acquired from
pelvis to skull base at 4 min per bed position with an axial
field of view of 15.7 cm and an 11-slice overlap between
bed positions, using a GE Discovery 710 PET-CT scanner
(GE Healthcare, Chicago, USA) at our institution. A low-
dose CT scan (140 kV, mA 15–100, noise index 40, 0.5-s
rotation time and 40 mm collimation) was performed at
the start of imaging to provide attenuation correction and
an anatomical reference. PET image reconstruction in-
cluded scanner-based corrections for radiotracer decay,
scatter, randoms and dead-time. Emission sinograms were
reconstructed with an ordered subset expectation
maximisation algorithm (2 iterations, 24 subsets) with
the scatter correction performed using the absolute scaling
of the scatter sinogram.
Scan analysis
All scans were assessed by two PET specialists (GC/
VW) in consensus using Hermes Hybrid Viewer (ver-
sion 2.6, Hermes Medical Solutions, Stockholm,
Sweden). To enable us to evaluate real life conditions,
the reviewers had knowledge of the patients’ relevant
clinical details including other imaging. A positive scan
was recorded if prostate, prostate bed, lymph node,
bone or focal visceral uptake was present above adja-
cent background tissues and could not be accounted for
by physiological or normal variation uptake [14].
Consensus was reached on all scans between the two
readers without the need to use a third reader. Scan
results were made available to the referring clinician
and prostate cancer MDM only after a pre-scan manage-
ment plan had been documented.
Statistical analysis
Data were tested for normality using the Shapiro-Wilk test.
Normally distributed data were expressed as mean ± standard
deviation. Non-normally distributed data were log-
transformed before comparison or displayed as median with
range. Statistical analyses were conducted using IBM SPSS
statistics software (version 24). A p value of < 0.05 was used
for statistical significance.
Results
Patient demographics
Fifty patients with high-risk, newly diagnosed prostate cancer
and 68 patients with BCR were consecutively evaluated.
Mean patient age was 65 years (range 48–85 years).
Demographic and pathological data are found in
Table 1. Gleason score for the HR group is taken from
prostate biopsy, whilst those from the BCR cohort are
taken from biopsy and/or prostatectomy specimen as ap-
plicable. Ten cases were reviewed by a clinical oncologist,
who provided clarification of the management plans.
HR group
The information acquired from 68Ga-THP-PSMA PET-CT
in 12 of the 50 scans (24 %) led to a change in
Table 1 Patient and disease characteristics of 118 scanned patients
Characteristic HR group BCR group
Age in years 65 years (48–85) 68.2 years (49–85)
PSA level (μg/L) 38.72 (1.61–265.1) 4.44 (0.16–71.02)
Gleason score 7 (3 + 3 to 5 + 5) 7 (3 + 3 to 5 + 4)
6 2 5
7 32 42
8 5 6
9 9 15
10 2 0
Pathological stage
T2a 7 5
T2b 9 20
T2c 6 10
T3a 10 16
T3b 18 15
T4 0 2
PSA doubling time N/A 9.06 months (1–40.9)
Data are means with ranges in parentheses
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management. Nine were inter-modality and 3 were intra-
modality (Table 2) (Fig. 1).
All 68Ga-THP-PSMA PET-CT scans demonstrated uptake
within the prostate. The SUVmax was significantly higher (p <
0.0001) in prostate cancer lesions (mean 7.08; 95% CI 5.67–
8.50) than in corresponding normal prostatic tissue (mean
1.89; 95% CI 1.68–2.09). The median ratio of SUVmax in
prostate cancer lesions to normal tissue in the same patient
was 3.1 (range 1.6–16.4).
All patients underwent a mpMRI scan as part of routine
diagnostic evaluation prior to 68Ga-THP-PSMA PET-CT.
Correlation with clinical parameters
34.6% (9/26) of patients with a management change had a
PSA < 20 μg/L whilst 12.5% (3/24) of patients with a man-
agement change had a PSA > 20 μg/L (Table 3).
Gleason score did not affect the proportion of patients who
had amanagement change (25.8%whenGleason < 8 and 25% if
> 8) but Gleason score > 8 was associated with more N1 disease
(25%, 4/16 vs 16.1%, 5/31) and more bone metastases (12.5%,
2/16 vs 6.5%, 2/31) (Table 4).
Staging
68Ga-THP-PSMA PET-CT identified 42 patients with N0 dis-
ease and 8 with N1 disease compared with 41 N0 and 9 N1 on
mpMRI. Regarding the presence of distant metastases, 3
extra-pelvic lymph nodes (M1a) and 4 bone (M1b) lesions
were identified on 68Ga-THP-PSMA PET-CT compared with
2 M1a and 2 M1b on mpMRI and bone scan.
Treatment plan
In 8 patients, pelvic lymph node dissection (PLND) was
planned at the time of radical prostatectomy, as they were
identified as ‘high-risk’ as per the D’Amico classification.
If pathological lymph nodes are identified on imaging, as
per standard UK practice, radical surgery is generally not
offered to patients, and radiotherapy or systemic treat-
ments are recommended instead. Following the 68Ga-
THP-PSMA PET-CT scan, pathological lymph nodes
were identified in 2/8 patients, with the remaining 6 hav-
ing negative scans for nodal disease. One patient
underwent a radical prostatectomy with PLND (as per
patient choice) with histologically positive nodes and the
second underwent radical radiotherapy and hormone treat-
ment. Of the remaining 6 patients (with negative 68Ga-
THP-PSMA PET-CT imaging), 4 underwent a PLND
due to high-risk clinical features. All removed lymph
nodes were benign. Two patients did not undergo PNLD
and are currently free of recurrence.
Follow-up
Follow-up is available for a median of 17 months
(range 1–23 months). In 46 patients, the 68Ga-THP-
PSMA PET-CT correctly staged the patient, as reflected
by their current follow-up, with the majority of patients
on PSA surveillance following radical treatment (robot-
assisted radical prostatectomy (RARP) or RT with an
undetectable PSA (defined as < 0.03 μg/L). One patient
has been referred back to his original hospital and we
do not have further follow-up data.
Three patients are having additional treatment. One had
RARP without PLND (no nodes identified by 68Ga-THP-
PSMA PET-CT). The PSA remained elevated post-
operatively and the patient has commenced hormones
and radiotherapy to the prostate bed on the assumption
that residual disease was present. The second patient had
a positive node on pre-RARP 68Ga-THP-PSMA PET-CT.
PLND was conducted but post-operative PSA remained
elevated and repeat 68Ga-THP-PSMA PET-CT confirmed
further nodal disease. The patient is now on hormone and
radiotherapy treatment. The final patient had a positive
surgical margin and therefore required radiotherapy to
the prostatic bed.
BCR group
Twenty-three of 68 (34%) patients had 68Ga-THP-PSMA
PET-CT scans that resulted in a management change.
Seventeen of the 23 (74%) were inter- rather than intra-
modality management changes, and details are outlined in
Table 5 (Fig. 2). Forty of the 68 68Ga-THP-PSMA PET-CT
scans demonstrated positive uptake (59%). The mean time
from primary treatment to BCR was 28 months (range 4–62
months) and 8 patients had a recurrence within 9 months of
their initial treatment.
Correlation with clinical parameters
68Ga-THP-PSMA PET-CTscan positivity was compared with
PSA values. Fifty nine percent of scans were positive (PSA
range 0.82–71.0 μg/L (mean 6.34)) whilst 41% were negative
(PSA range 0.11–14.2 μg/L mean 1.7, p < 0.001) (Fig. 3). No
positive scans were identified when the PSAwas < 0.5 μg/L.
Management change was seen in 4/17 (23.5%) patients with
PSA levels between 0.5 and 1.0 μg/L with higher but broadly
similar proportions of changes in management in patients with
PSA 1.0–2.0 μg/L (6/14, 42.9%), PSA 2.0–5.0 μg/L (7/15,
46.7%), PSA 5.0–10.0 μg/L (4/11, 36.4%) and PSA > 10.0
μg/L (2/5 (40%) (Fig. 4).
PSAdt at diagnosis was available for 60 patients and
Gleason scores for 62, as a proportion of patients were diag-
nosed and treated in external hospitals. For those with a PSAdt
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< 6 months, 14/25 (56%) had a positive scan compared with
16/35 (45.7%) > 6 months (Fig. 5). Management changed was
in 9/25 (36%) of those with PSAdt < 6 months and 9/35
(25.7%) of those with PSAdt > 6 months.
Twenty-two out of 43 (51.2%) patients with a Gleason
score < 8 had a positive scan compared with 15/19 (78.9%)
of those with a Gleason score > 8 (Fig. 6). Management
changed was in 13/43 (30.2%) patients with Gleason < 8
and in 7/19 (36.8%) of patients with Gleason > 8.
Follow-up
Follow-up is available for a median of 13 months (range 2
to 18 months) for the total cohort from the date of the
68Ga-THP-PSMA PET-CT. Currently, 27 men are on
PSA surveillance, 22 on androgen deprivation therapy
(ADT), 10 are having chemotherapy (2 with hormone-
sensitive disease, 8 with castrate-resistant metastatic
prostate cancer), 4 undergoing radiotherapy, 2 on watchful
waiting, 2 having best supportive care (due to metastatic
tumours of non-prostatic origin) and 1 being considered
for salvage surgery. In 61 of the 68 BCR patients, subse-
quent follow-up has not been discordant with 68Ga-THP-
PSMA PET-CT results.
In 7 patients, the 68Ga-THP-PSMA PET-CT scan was
negative, but all patients have now been taken off PSA
surveillance. In 5 of these patients, despite a negative
68Ga-THP-PSMA PET-CT scan, there is ongoing concern
about micro-metastatic disease due to a continuing rise in
PSA; 1 is having more intensive PSA surveillance (PSA
1.42 μg/L), 2 have commenced ADT (PSA 1.98 μg/L and
1.2 μg/L, respectively) and 2 are on chemotherapy (PSA
1.37 μg/L and 1.67 μg/L, respectively). In the other 2
patients, the initial 68Ga-THP-PSMA PET-CT scan was
reassuring. However, due to rising PSA, the scan was
repeated (at 6 and 9 months, respectively), and nodal dis-
ease has now been demonstrated. The first of these two
patients is on ADT and the other on watchful waiting.
Whilst the majority of patients had multi-modal treat-
ment and subsequently underwent a 68Ga-THP-PSMA
PET-CT scan, only minor differences were identified
between those with previous primary RARP compared
with RT. 34.7% of patients who had a RARP had a
change in management compared with 39.1% who had
RT.
Discussion
Our study has demonstrated a clinically significant impact on
the management of patients with high-risk prostate cancer and
BCR, imaged using 68Ga-THP-PSMA PET-CT.
Fig. 1 68Ga-THP-PSMAPET-CTscan of a man diagnosedwith high-risk
prostate cancer. a Maximum intensity projection image. b The primary
tumour shows focal activity in the left peripheral zone (arrow). c There is
evidence of retroperitoneal nodal disease (arrow) and d bone metastases
(arrow). The detection of metastatic disease changed management from a
surgical to systemic therapy approach with hormones and chemotherapy
Table 2 Type of management change in primary diagnosis high-risk
cohort following 68Ga-THP-PSMA PET-CT scan
Initial management plan Revised management plan (n =
12)
RARP with PLND RARP without PLND (n = 3)
RARP without PLND RARP and PLND (n = 1)
RT & ADT (n = 1)
ADT alone (n = 1)
Radiotherapy
(including in combination with
ADT)
Brachytherapy (n = 1)
ADT alone (n = 2)
ADT and chemotherapy (n = 1)
ADT alone RT and ADT (n = 1)
ADT and chemotherapy (n = 1)
Eur J Nucl Med Mol Imaging
Primary staging in high-risk prostate cancer
In our series of patients undergoing 68Ga-THP-PSMA
PET-CT for primary staging, a management change (com-
pared with the decision made in an MDM using standard
diagnostic techniques) was noted in 12 of the 50 patients
(24%). Roach et al. evaluated a comparable cohort of 108
patients scanned for primary staging and reported a 21%
management change [17].
We noted a higher number of management changes
in patients with PSA < 20 μg/L (34.6%) compared with
patients with PSA > 20 μg/L (12.5%). This implies that
at high PSA levels, conventional staging with MRI,
bone scan and/or CT can detect nodal or metastatic dis-
ease, but at lower PSA levels, 68Ga-THP-PSMA PET-
CT has greater sensitivity and management impact. We
did not find a difference in management changes be-
tween patients with Gleason score < 8 and > 8.
Perera et al. analysed 16 studies involving 1309 pa-
tients who underwent a 68Ga-PSMA PET-CT (most used
68Ga-HBED-CC-PSMA, some did not mention the specif-
ic ligand), of which 40% of scans were positive for pa-
tients undergoing primary staging (95% CI 19–64%) [12].
Four studies were evaluated for the predictive ability of PSMA
PET-CT (scan positivity compared with histology), demonstrat-
ing a sensitivity of 80% and specificity of 97%.
Lymph node evaluation is integral to primary staging
and there is a need for imaging which provides more
sensitive detection in high-risk prostate cancer. Current
practice regarding lymphadenectomy is reliant on pre-
operative models using PSA levels, Gleason score and
T-stage to dictate surgical planning [19].
Whilst our aim was not to specifically measure the
accuracy of nodal detection, 68Ga-THP-PSMA PET-CT
identified lymph nodes in 8/50 patients (16%). In 2
patients, identification of lymphadenopathy led to a
management change: one to RARP with a unilateral
PLND (histologically positive node) and one to radio-
therapy and hormones instead of RARP.
A number of studies have evaluated the sensitivity
and specificity of 68Ga-HBED-CC-PSMA PET-CT for
lymph node detection. Sensitivity is reported as between
33.3–65.9% and specificity 98.9–100% [21, 22]. Budäus
et al. reported that 68Ga-PSMA PET-CT scans identified
4 of 12 patients (33.3%) as node positive. In 8 patients
with histologically confirmed lymph nodes, 68Ga-PSMA
PET-CT was negative, giving a false-negative value of
66.7%.
Current EAU guidelines recognise that PLND are as-
sociated with worse peri- and postoperative outcomes,
whilst a direct therapeutic effect is still not evident from
the current literature. Thus, it is not our routine practice to
offer surgery and lymph node dissection to patients with
pathological nodes on imaging. A recent review of UK
practice in 2017 demonstrated that most radical prostatec-
tomies are performed for patients with Gleason grade
group 2 and 3 disease (intermediate risk). Lymph node
dissection rates were similar across all grade groups rang-
ing from 13–15% [23].
In our cohort, 68Ga-THP-PSMA PET-CT detected 7
patients with metastatic disease at primary presentation
(3 M1a and 4 M1b), which was greater than that iden-
tified by conventional imaging alone. Treatment choice
did change as a result of these findings in 4/7 patients
(57%).
Biochemical recurrence
In our BCR group undergoing 68Ga-THP-PSMA PET-CT,
clinical management changed in 23 of the 68 patients
(34%), with 59% of scans demonstrating positivity. In
23 scans, disease recurrence was identified locally (pros-
tate or prostate bed), 23 in lymph nodes and in 9, meta-
static disease was seen. In those where there was a man-
agement change, 10 patients were upstaged (42%) and 2
downstaged (8.3%), and in 12 scans (50%), staging was
concordant with that of conventional imaging, but addi-
tional information relevant to treatment planning was
identified.
Roach et al. in Australia and Afaq et al. in the UK
have shown 62% and 39% change in management intent,
respectively, in the BCR setting, with the use of 68Ga-
HBED-CC-PSMA [17, 18]. Roach et al. have conducted
the largest prospective multicentre study of 323 patients
evaluating management intent. They evaluated all patients
Table 3 Management change (%) in primary diagnosis high-risk cohort
as related to PSA and TNM stage
PSA < 20 (n = 9/26) 34.6% > 20 (n = 3/24) 12.5%
N1 4 5
M1a 0 3
M1b 4 0
Table 4 Management change (%) in primary diagnosis high-risk cohort
as related to Gleason score and TNM stage
Gleason < 8 (n = 8/31) 25.8% > 8 (n = 4/16) 25%
N1 16.1% 25%
M1a 6.5% 6.3%
M1b 6.5% 15
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undergoing imaging for BCR, with a detectable PSA but
negative conventional imaging. Overall clinical intent
changed in 51% of patients following results of PSMA
PET-CT. 68Ga-HBED-CC-PSMA PET-CT detected addi-
tional local disease in 27% of patients, nodes in 39%
and metastatic disease in 16%.
The systematic review by Han et al., evaluating management
changes following 68Ga-HBED-CC-PSMA PET, was performed
for BCR in 11 studies [24]. The proportion undergoing RT in-
creased from 56 to 61%, typically with an increase in dose or
target volume. There was an increase in patients undergoing sal-
vage surgery from 1 to 7%, which included performing pelvic
Fig. 2 68Ga-THP-PSMA PET-CT scan of a man with a rising PSA (3
μg/L) after a previous radical prostatectomy. a Maximum intensity pro-
jection image. b There is evidence of nodal disease in the left
supraclavicular fossa (arrow) and c retroperitoneum (arrow) as well as d
a vertebral bone metastasis (arrow)
Table 5 Type of management change in BCR cohort following 68Ga-THP-PSMA PET-CT
Management plan
pre-PSMA PET-CT
Patients who had
management changed
New management plan post-PSMA PET-CT Patients who did not have
management changed
Surveillance 3 ADT (n = 1) 11
ADT and chemotherapy (n = 1)
SABR (n = 1)
RARP 2 Surveillance (n = 1) 6
ADT (n = 1)
Brachytherapy 2 Surveillance (n = 1) 1
Watchful waiting (n = 1)
SABR 2 EBRT (n = 1) 5
ADT (n = 1)
EBRT 5 Surveillance (n = 1) 13
ADT (n = 2)
SABR (n = 1)
RARP (n = 1)
ADT 9 Best supportive care (n = 1) 9
ADT and chemotherapy (n = 3)
Chemotherapy (n = 3)
EBRT (n = 1)
SABR (n = 1)
ADT androgen deprivation therapy, SABR stereotactic ablative radiotherapy, EBRT external beam radiotherapy, RARP robotic-assisted radical
prostatectomy
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lymph node dissection (in our group, this decreased from 10.2 to
5.9%). The number of patients undergoing systemic treatment
decreased from 26 to 12% (in our cohort, it increased from 5.9
to 10.2%). ADTwas initially planned in 144 patients but was only
commenced in 52 patients after 68Ga-HBED-CC-PSMA (in our
group, planned in 28% and decreased to 25%). The proportion of
patients with no treatment decision or on surveillance decreased
from 14 to 11% (we report an increase from 29.4 to 38%). In
addition, we report a small decrease in numbers undergoing radio-
therapy (from 26.4 to 21%).
At PSA levels of 1.0 μg/L and above, we noted
higher rates of management change (0% < 0.5 μg/L,
23% 0.5–1 μg/L, 46% 1–2 μg/L). Higher scan positivity
and change in management rates were also seen in pa-
tients with short PSAdt < 6 months (56% vs 45.7% and
36.0% vs 25.7%, respectively). Similarly, those with
higher Gleason scores > 8 had higher scan positivity
rates (78.9% vs 51.2%) but broadly similar changes in
management (36.8% vs 30.2%).
Fendler et al. using 68Ga-HBED-CC-PSMA PET-CT
reported a detection rate of 75% in BCR. There was a
significant increase in detection rate across PSA ranges,
38% for < 0.5 ng/mL, 57% for 0.5–< 1 ng/mL and 84%
for 1.0 ng/mL [25]. There were 8 cases where the PET
findings were reported as negative but histology con-
firmed prostate cancer.
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Similar trends were identified in a retrospective series
by Ceci et al. regarding factors which correlated with
68Ga-HBED-CC-PSMA PET-CT detection in patients pre-
senting with BCR [26].
68Ga-HBED-CC-PSMA PET-CT was positive in 23 of
39 patients (59 %) with PSA < 2 μg/L. These results are
consistent with data recently reported by Afshar-Oromieh
et al. who reported scan positivity rates with 68Ga-HBED-
CC-PSMA PET-CT of 61.1% in 90 patients with PSA < 2
μg/L [27]. PSA kinetics were evaluated, reporting that
68Ga-HBED-CC-PSMA PET-CT was positive in 85% of
patients with low PSA values and short PSAdt, but in
only 18.7% of patients with low PSA and long PSAdt.
For Perera et al. in the BCR cohort, 68Ga-HBED-CC-
PSMA PET positivity increased as serum PSA rose. For
those with a PSA < 0.2 μg/L, the detection rate was
42%, which increased to 58%, 76%, and 95% for the
0.2–0.99, 1.00–1.99, and > 2.0ug/L PSA values, respec-
tively [12]. A similar trend was demonstrated with
PSAdt, with a PSMA positivity of 92% for those with
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a PSAdt < 6 months and 64% for those ≥ 6 months.
The authors again recognise the significant heterogene-
ity between the groups analysed.
Several studies have determined that the clinical de-
tection rate was dependent on the PSA level, with
Derlin et al. reporting rates as high as 94.1% for PSA
> 10 μg/L, 54.5% for PSA 1–2 μg/L and 20% below
0.5 μg/L [28]. Afaq et al., using 68Ga-HBED-CC-
PSMA, reported an overall scan positive rate of 15.8%
(PSA 0.2–0.5 μg/L), 33% (PSA 0.5–1 μg/L), 20% (PSA
1–2 μg/L) and 84.6% (PSA 2–5 μg/L) [18].
The difference in management change and scan positivity
rates between these studies and ours might be explained by
differences in prospective versus retrospective methodology,
referral patterns and decision-making between Australian,
European and UK practice. The data from Afaq et al., a
UK study in the same city, is more comparable with ours
and hence the closer values for management impact [18].
Whilst previous studies have reported higher detec-
tion rates with other PSMA ligands, 68Ga-THP-PSMA
demonstrated reasonable detection rates in patients with
BCR and PSA levels ≥ 1 μg/L. Potential explanations
for the lower detection rates at very low PSA levels
using this ligand compared with 68Ga-HBED-CC-
PSMA include different use of ADT between studies
which alters PSMA expression, faster renal clearance
of THP compared with HBED and potential lower af-
finity of 68Ga-THP-PSMA. No comparisons have been
performed to determine if this impacts on diagnostic
accuracy or management.
68Ga-THP-PSMA
68Ga-THP-PSMA can be labelled to Good Manufacturing
Practice criteria in 5 min at room temperature as a single-
step technique and has a potential practical and cost ad-
vantage over other 68Ga-labelled PSMA radiopharmaceuti-
cals. Hofman et al., Young et al. and Derlin et al. have
evaluated this ligand for its safety and bio-distribution,
whole-body radiation dose, plasma clearance and correla-
tion of uptake with tumour PSMA expression on histopa-
thology [14, 15]. They demonstrated that 68Ga-THP-PSMA
had lower background uptake in salivary glands, liver and
spleen than 68Ga-HBED-CC-PSMA. Metastatic lesions were
equally identified on both HBED-PSMA and THP-PSMA-
PET scans. 68Ga-THP-PSMA provides a similar effective dose
to that published for 68Ga-HBED-CC-PSMA (2.07 × 10−2
mSv/MBq).
Limitations
This is a single-centre study and may not reflect practice
in other units where diagnostic and treatment guidelines
may differ. Nevertheless, the results reflect practice in a
busy tertiary referral centre with a large surgical and on-
cological prostate cancer service. Management decisions
were made in a multidisciplinary fashion for a consecutive
cohort of patients. The study reports intended management
and did not take into account actual treatment, which may
on occasion differ from planned due to patient comorbid-
ities or other patient-related factors. Not all of the PET-
positive finding scans were validated by another procedure
such as histological analysis of lymph nodes or visceral
lesions (not always feasible) or conventional imaging.
Conclusions
Our study of a new radiopharmaceutical PSMA formu-
lation that can be rapidly manufactured from a 68Ga
generator and cold-kit vial demonstrates that 68Ga-
THP-PSMA PET-CT impacts on management decisions
in HR prostate cancer prior to radical therapy and BCR,
despite lower scan positivity rates at PSA levels < 0.5
μg/L. Scan positivity is related to PSA level, PSA dou-
bling time and Gleason score.
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